Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drops could help kids see clearly longer

NCT ID NCT06579287

Disease control Sponsor: Sunhawk Vision Biotech, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new eye drop called SHJ002 to see if it can safely slow down worsening nearsightedness (myopia) in children ages 3 to 12. The drop works by targeting a specific molecule in the eye. Researchers will compare it to a standard treatment, atropine, and measure changes in vision and eye length over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

140 people

The number who actually took part.

Started

Jan 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

3 to 12 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Be male or female, age 3-12 years (inclusive). 2. Cycloplegic sphere of -1.00 D or worse in both eyes 3. Able to complete all study assessments and comply with the protocol 4. Literate or able to orally communicate. 5. Parent or guardian able and willing to provide written informed consent 6. Parent or guardian able and willing to assure subject compliance with the protocol, follow study instructions, and attend study visits 7. Able to tolerate eye drops in both eyes. 8. Be able and willing to avoid all disallowed medications and refractive correction 9. For female subjects of childbearing potential (those who have experienced menarche and who are not surgically sterilized \[bilateral tubal ligation, hysterectomy, or bilateral oophorectomy\]), a negative urinary test. 10. Women of childbearing potential must agree to use two reliable methods of contraception 11. Males not naturally or surgically sterile, who have a female partner of childbearing potential, must agree to use two reliable methods of contraception Exclusion Criteria: 1. Axial length \> 26 mm 2. Anisometropia 3. Astigmatism \> 2.00 D 4. Intraocular pressure \> 21 mm Hg or \< 6 mm Hg 5. Active or recent history of severe ocular infection or inflammation 6. Previous incisional or laser surgery 7. Any clinically significant finding on slit lamp biomicroscopy or ophthalmoscopy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myopia, progressive are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

degenerative myopia myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myopia, progressive

Contacts and locations

Locations

  • Cathay General Hospital

    Taipei, 106, Taiwan

  • Chang Cung Memorial Hospital-Tucheng

    New Taipei City, 236, Taiwan

  • Changhua Christian Hospital

    Chang-hua, Taiwan

  • Chung Shan Medical University Hospital

    Taichung, 402, Taiwan

  • Kaohsiung Veterans General Hospital

    Kaohsiung City, 813, Taiwan

  • MacKay Memorial Hospital-Tamsui

    New Taipei City, 251, Taiwan

  • Pacific Center for Advanced Vision Care Tanasbourne Vision Center

    Hillsboro, Ohio, 97124, United States

  • Taipei Veterans General Hospital

    Taipei, 201, Taiwan

  • Tri-Service General Hospital

    Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.